Abstract
Dyslipidemia is common in patients with renal disease, may contribute to the high incidence of cardiovascular disease, and may play a role in progressive renal injury. Recent studies have shown that newer antilipemic agents appear to be safe and effective in patients with renal disease. This should make it possible to conduct large, controlled clinical trials examining the effect of lipid-lowering strategies on cardiovascular disease, and on renal disease progression.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 141-146 |
| Number of pages | 6 |
| Journal | Current opinion in nephrology and hypertension |
| Volume | 5 |
| Issue number | 2 |
| DOIs | |
| State | Published - Jan 1 1996 |
